Carl Dambkowski Sells 3,520 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 3,520 shares of the stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $40.69, for a total value of $143,228.80. Following the sale, the insider now owns 252,623 shares of the company’s stock, valued at $10,279,229.87. This represents a 1.37 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Carl Dambkowski also recently made the following trade(s):

• On Thursday, January 2nd, Carl Dambkowski sold 4,085 shares of Apogee Therapeutics stock. The stock was sold at an average price of $46.94, for a total value of $191,749.90.
• On Wednesday, December 11th, Carl Dambkowski sold 4,540 shares of Apogee Therapeutics stock. The shares were sold at an average price of $48.76, for a total transaction of $221,370.40.
• On Wednesday, December 4th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $46.07, for a total transaction of $307,056.55.

Apogee Therapeutics Price Performance

Shares of APGE traded down $1.92 during midday trading on Friday, hitting $39.72. The stock had a trading volume of 385,519 shares, compared to its average volume of 506,977. The firm has a market cap of $1.79 billion, a PE ratio of -16.41 and a beta of 2.18. Apogee Therapeutics, Inc. has a 1 year low of $33.14 and a 1 year high of $72.29. The stock’s 50 day moving average is $44.25 and its 200 day moving average is $48.53.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.13). As a group, equities research analysts expect that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current fiscal year.

Institutional Trading of Apogee Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Apogee Therapeutics during the 3rd quarter worth about $71,000. Mirae Asset Global Investments Co. Ltd. raised its position in Apogee Therapeutics by 21.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company’s stock worth $94,000 after buying an additional 285 shares during the last quarter. Aigen Investment Management LP acquired a new stake in Apogee Therapeutics during the 4th quarter valued at approximately $216,000. Wexford Capital LP purchased a new stake in shares of Apogee Therapeutics in the 3rd quarter valued at $230,000. Finally, Arizona State Retirement System increased its stake in shares of Apogee Therapeutics by 17.3% in the fourth quarter. Arizona State Retirement System now owns 6,517 shares of the company’s stock worth $295,000 after acquiring an additional 960 shares during the period. Institutional investors and hedge funds own 79.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on APGE. Guggenheim reaffirmed a “buy” rating on shares of Apogee Therapeutics in a research note on Thursday, December 12th. Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating and a $89.00 price target on the stock. Canaccord Genuity Group initiated coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 price objective for the company. Finally, Wedbush boosted their target price on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the stock an “outperform” rating in a report on Monday, December 2nd. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $89.71.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.